[Congressional Record Volume 170, Number 114 (Wednesday, July 10, 2024)]
[Senate]
[Pages S4525-S4526]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SA 2244. Mrs. SHAHEEN (for herself and Ms. Collins) submitted an
amendment intended to be proposed by her to the bill S. 4638, to
authorize appropriations for fiscal year 2025 for military activities
of the Department of Defense, for military construction, and for
defense activities of the Department of Energy, to prescribe military
personnel strengths for such fiscal year, and for other purposes; which
was ordered to lie on the table; as follows:
At the end of subtitle H of title X, insert the following:
SEC. 1095. PFAS HEALTH EFFECTS ASSESSMENT, RECOMMENDATIONS,
AND GUIDANCE.
(a) Periodic Assessment and Recommendations.--
(1) Agreement.--The Director of the Agency for Toxic
Substances and Disease Registry (in this section referred to
as the ``Director'') shall enter into an agreement with the
National Academies of Sciences, Engineering, and Medicine (or
another appropriate entity if the National Academies declines
to enter into such agreement) under which the National
Academies or the other appropriate entity agrees--
(A) to assess the health effects of per- and
polyfluoroalkyl substances (in this section referred to as
``PFAS'') that can be measured in human tissues;
[[Page S4526]]
(B) to formulate clinical recommendations on addressing
such health effects;
(C) not later than 2 years after the date of entry into
such agreement, to complete the initial assessment under
subparagraph (A) and formulate the initial recommendations
under subparagraph (B); and
(D) to update the most recent assessment and
recommendations under this paragraph--
(i) every 5 years; or
(ii) more frequently as determined necessary by the
Director based on an assessment of the science.
(2) Consultation.--In carrying out the assessments under
paragraph (1), the National Academies of Sciences,
Engineering, and Medicine or other appropriate entity shall
engage with PFAS exposed communities and solicit input from
members of such communities regarding their experiences with
PFAS exposure, testing, and clinical follow-up.
(3) Timing of entry into agreement.--The Director shall
enter into the agreement required by paragraph (1) not later
than 60 days after the date of enactment of this Act.
(b) Up-to-Date Guidance.--Based on the results of the most
recent assessment and recommendations under subsection (a),
the Director, in consultation with the entity with which the
Director enters into the agreement under subsection (a),
shall--
(1) not later than 5 years after the date of entry into the
agreement required by subsection (a)--
(A) issue up-to-date clinical guidance on addressing the
health effects of PFAS;
(B) post such guidance on the public website of the Agency
for Toxic Substances and Disease Registry; and
(C) disseminate such guidance to State and local public
health authorities and appropriate health care professionals;
and
(2) every 5 years thereafter, or more frequently as
determined necessary by the Director based on an assessment
of the science, issue, post, and disseminate up-to-date
guidance as described in paragraph (1).
______